Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 250

The DOI matches its Crossref record.

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure

NACB WRITING GROUP MEMBERS, Wu, A. H.B., Jaffe, A. S., Apple, F. S., Jesse, R. L., Francis, G. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Tang, W.H. W., Christenson, R. H., NACB COMMITTEE MEMBERS, Christenson, R. H., Apple, F. S., Cannon, C. P., Francis, G. L., Jesse, R. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Storrow, A. B., Tang, W.H. W., Wu, A. H.B.·2007·Clinical Chemistry

Abstract

I. OVERVIEW OF OTHER ETIOLOGIES…5 A. Background and Scope…5 II. USE OF CARDIAC BIOMARKERS IN THE EVALUATION OF PATIENTS WITH CHRONIC RENAL FAILURE …7 A. Utilization of cardiac biochemical marker in the setting of chronic renal failure …7 1. Biomarkers in chronic renal failure…8 III. USE OF BIOMARKERS IN THE EVALUATION OF OTHER NONISCHEMIC ETIOLOGIES …11 A. Utilization of Cardiac Biochemical Marker in the Setting of Nonischemic Etiologies…11 1. Cardiac troponin and BNP/NTproBNP in other nonischemic etiologies…12 2. Cardiac troponin and BNP/NTproBNP in pulmonary embolism…12 3. Cardiac troponin in critical care patients…14 IV. USE OF BIOMARKERS AFTER NONCARDIAC SURGERY …14 A. Use of Cardiac Biochemical Markers after Noncardiac Surgery…14 1. Biomarkers after noncardiac surgery…15 V. BIOMARKER USE AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI). …16 A. Use of Cardiac Biochemical Markers after PCI …16 1. Biomarkers after PCI…17 VI. USE OF BIOMARKERS AFTER CARDIAC SURGERY…18 A. Utilization of Cardiac Biochemical Markers after Cardiac Surgery …18 1. Biomarkers after cardiac surgery…19 VII. REFERENCES …21 Over the past decade, cardiac troponin (cTn)1 has become the cornerstone laboratory medicine measurement for assessment of myocardial infarction (MI) in suspected acute coronary syndrome (ACS) patients. In the past 5–7 years, methods for measuring the natriuretic peptide B-type natriuretic peptide (BNP) and its inert cometabolite N-terminal proBNP (NT-proBNP) have become available, and much knowledge has accumulated regarding their clinical use in the context of heart failure and hemodynamic stress. In addition to ACS and heart failure, there are common and clinically important patient cohorts in whom these measurements can aid in diagnosis and management. For this reason, the National Academy of Clinical Biochemistry (NACB) formed a Laboratory Medicine Practice Guidelines (LMPG) committee to extend cardiac biochemical marker recommendations and establish modern guidelines for utilization in etiologies other than ACS and heart failure. During development, updated draft revisions of the guidelines were prepared and placed for comment on the NACB World Wide Web site (http://www.aacc.org/AACC/members/nacb/LMPG/OnlineGuide/DraftGuidelines/BioHearFailure/) beginning in August 2004. The draft LMPG and suggested revisions were presented for public and stakeholder comment at the October 2004 Arnold O. Beckman Conference titled Cardiac Markers: Establishing Guidelines and Improving Results. The resulting draft guidelines can be viewed in their entirety at on the NACB World Wide Web site (http://www.aacc.org/AACC/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/ACSHeart/heartpdf.htm). The scope of the guidelines presented here represent the writing group’s recommendations for cTn, BNP, and NT-proBNP in the rapidly evolving area of etiologies other than ACS and heart failure in adult patients. Other sections of the biochemical cardiac marker guidelines involving clinical and analytical issues of ACS and heart failure and issues of logistics and point-of-care testing are available at http://www.aacc.org/AACC/members/nacb/LMPG/OnlineGuide/PublishedGuidelines. More explicit detail on guideline development and the groups providing stakeholder input is available in the Preamble to the overall guideline, which is available at http://www.aacc.org/AACC/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/ACSHeart/heartpdf.htm. The writing group of this document represents a multidisciplinary subcommittee consisting of laboratorians and specialist clinicians from the NACB guidelines committee with the addition of 1 ad hoc member (A.S.J.). The process for developing the recommendations was collaborative and iterative with input from all members of the writing group; the effort and process was chaired by R.H.C.; write-up of the document was spearheaded by the section leader A.H.B.W. The strength of scientific data supporting each recommendation is characterized using the scoring criteria adopted from the American Heart Association/American College of Cardiology, as summarized in Table 11 . For each recommendation, the designations I, IIa, IIb, and III describe the indications, and the uppercase letters A through C describe the weight of evidence. The target groups for this guideline are both laboratory professionals and clinicians. These guidelines were developed with best available evidence and incorporated substantial input from acknowledged experts and professional organizations. As such, they represent the current best practice for utilization of biochemical cardiac markers in etiologies other than ACS and heart failure. Currently available cardiac biomarkers can define cell death, damage, or dysfunction to particular organ systems but cannot define the mechanisms of the effects seen. Cardiologists, emergency medicine physicians, and clinical laboratorians have often acted as if cardiac biomarkers such as cardiac troponins T (cTnT) and

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/clinchem.2007.095679

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 250

Metadata

Authors
NACB WRITING GROUP MEMBERS, Wu, A. H. B., Jaffe, A. S., Apple, F. S., Jesse, R. L., Francis, G. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Tang, W. H. W., Christenson, R. H., NACB COMMITTEE MEMBERS, Christenson, R. H., Apple, F. S., Cannon, C. P., Francis, G. L., Jesse, R. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Storrow, A. B., Tang, W. H. W., & Wu, A. H. B.
Venue
Clinical Chemistry
Published
2007-10-05
Volume
53
Issue
12
Pages
2086-2096
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2109494884
Cited by
250
References
0
FWCI
10.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure. https://app.cochat.ai/papers/10.1373/clinchem.2007.095679
The paper
NACB WRITING GROUP MEMBERS, Wu, A. H. B., Jaffe, A. S., Apple, F. S., Jesse, R. L., Francis, G. L., Morrow, D. A., Newby, L. K., Ravkilde, J., Tang, W. H. W., Christenson, R. H., NACB COMMITTEE MEMBERS, Christenson, R. H., Apple, F. S., Cannon, C. P., Francis, G. L., Jesse, R. L., Morrow, D. A., Newby, L. K., . . . Wu, A. H. B. (2007). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure. Clinical Chemistry. https://doi.org/10.1373/clinchem.2007.095679

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.